Coster and Lindal have announced that they will each transfer their pharmaceutical aerosol businesses into a new company called RxPack, which will operate independently of both parent companies. RxPack will distribute Coster’s aerosol filling equipment in addition to manufacturing MDIs, nasal spray pumps, and other OINDP devices; Coster and Lindal will continue to compete in the pharmaceutical bag-on-valve aerosol market as well as in other markets.
RxPack, which will take over a Lindal production facility in Oggiono, Italy, expects to start operations with approximately 60 employees in 2021, with the intention to hire additional staff in the future. Each of the parent companies is expected to invest €4 million for upgrades to the Oggiono facility. According to the announcement, “Further investments and R&D plans will target entering the highly attractive regulated sector and extending the product portfolio with innovative alternative pharmaceutical packaging solutions.”
Coster Chair of the Board Martina Segatta said, “Our goal is to create a new strong player in the field of packaging solutions for pharmaceutical applications. RxPack has the expertise, the products and the financial strength to provide our pharmaceutical customers with innovative solutions that significantly improve the health and lives of sick people. With RxPack, we create a powerful setup dedicated to the pharmaceutical sector that will enable us to serve this mission excellently and make the most of the opportunities in this sector.”
Lindal Chairwoman of the Board Katharina Lilienthal commented, “RxPack is being established to take our pharmaceutical business to the next level and to create momentum in the pharmaceutical packaging sector. With its distinctive product portfolio and its strong financial resources, RxPack is ideally positioned to grow in the non-regulated sector and to enter the highly attractive regulated sector.”
Read the Coster press release.
Read the Lindal press release.
